GlassScriptPhysician profile
James H Bowers
NPI 1851330468
$5,844.49
in general payments reported to CMS, 2019-2025
30 companies · $762 in 2025
The $762 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,420 · 2020: $446 · 2021: $982 · 2022: $822 · 2023: $743 · 2024: $669 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,172 · Education: $2.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,171.53 |
| Education | $2.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $742.83 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $680.68 | 2019-2025 | |
| Amgen INC. | $657.91 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $645.89 | 2019-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $623.82 | 2019-2022 | |
| Novo Nordisk INC | $527.39 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $319.16 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $250.20 | 2019-2025 | Farxiga, Wainua |
| Sanofi-Aventis U.S. LLC | $226.66 | 2019-2023 | |
| Abbott Laboratories | $219.96 | 2019-2024 | Jot Dx, Mitraclip |
| Shockwave Medical, INC | $97.06 | 2022 | |
| Edwards Lifesciences Corporation | $87.67 | 2019-2023 | Sapien 3 Ultra Resilia |
| Kiniksa Pharmaceuticals International, Plc | $84.66 | 2024 | Arcalyst |
| Celgene Corporation | $75.84 | 2023 | Camzyos |
| Lexicon Pharmaceuticals, INC. | $71.56 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $66.03 | 2020 | |
| Gilead Sciences, INC. | $59.98 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $51.16 | 2019 | |
| Alnylam Pharmaceuticals INC. | $48.11 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.52 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $43.90 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $42.50 | 2021-2022 | |
| Medtronic Vascular, INC. | $38.92 | 2019 | |
| Arbor Pharmaceuticals, INC. | $27.07 | 2019 | |
| Esperion Therapeutics, INC. | $24.99 | 2025 | Nexletol |
| Scpharmaceuticals INC. | $22.55 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.77 | 2021 | |
| Heartflow, INC. | $16.64 | 2023 | Ffrct |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.06 | 2025 | Lifevest |
| Allergan, INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.